scispace - formally typeset
J

Janet Hoenicka

Researcher at University of Granada

Publications -  86
Citations -  6789

Janet Hoenicka is an academic researcher from University of Granada. The author has contributed to research in topics: Gene & ANKK1. The author has an hindex of 29, co-authored 76 publications receiving 5698 citations. Previous affiliations of Janet Hoenicka include Spanish National Research Council & Autonomous University of Madrid.

Papers
More filters
Journal ArticleDOI

The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia.

TL;DR: Dementia with Lewy bodies is related to mutation of α‐synuclein, and the novel mutation, that substitutes a dicarboxylic amino acid, glutamic acid, with a basic amino acid in a much conserved area of the protein, is likely to produce severe disturbance of protein function.
Journal ArticleDOI

Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies

Mike A. Nalls, +248 more
- 01 Dec 2019 - 
TL;DR: These data provide the most comprehensive survey of genetic risk within Parkinson's disease to date, providing a biological context for these risk factors, and showing that a considerable genetic component of this disease remains unidentified.
Journal ArticleDOI

The complete DNA sequence of yeast chromosome III.

Stephen G. Oliver, +146 more
- 07 May 1992 - 
TL;DR: The entire DNA sequence of chromosome III of the yeast Saccharomyces cerevisiae has been determined, which is the first complete sequence analysis of an entire chromosome from any organism.
Journal ArticleDOI

Impulsivity and Sustained Attention in Pathological Gamblers: Influence of Childhood ADHD History

TL;DR: It is shown that patients in the PG-ADHD group exhibit a significantly lower capacity to delay gratification than those in thePG-non-ADhd and control groups, and less inhibitory control than patients inThe PG- non- ADHD group.
Journal ArticleDOI

Depression in Parkinson's disease is related to a genetic polymorphism of the cannabinoid receptor gene (CNR1).

TL;DR: In patients with PD, the presence of two long alleles, with more than 16 repeated AAT trinucleotides in the CNR1 gene, was associated with a reduced prevalence of depression, suggesting that the pharmacological manipulation of cannabinoid neurotransmission could open a new therapeutic approach for the treatment of depression in PD and possibly in other conditions.